Background: Permanent His bundle pacing (HBP) is a physiological alternative to right ventricular pacing. It is not known whether HBP can cause His-Purkinje conduction (HPC) disease. The aim of our study is to assess His bundle capture and its effect on left ventricular (LV) function in longterm follow-up and to determine HPC at the time of pulse generator change (GC) in patients with chronic HBP.
INTRODUCTION
Right ventricular pacing (RVP) has been associated with ventricular dyssynchrony, reduction in left ventricular ejection fraction (LVEF), and adverse clinical outcomes. [1] [2] [3] Permanent His bundle pacing (HBP) is a physiologic alternative to RVP. Deshmukh et al. 4 first described successful permanent HBP in a small series of patients with atrial fibrillation (AF) and dilated cardiomyopathy in 2000. Subsequently, there have been multiple reports on permanent HBP, which have demonstrated that it is feasible and associated with an improvement in exercise capacity, myocardial perfusion, ventricular synchrony, and LVEF compared to RVP. [5] [6] [7] [8] [9] Despite these studies, permanent HBP has not gained widespread acceptance in clinical practice due to a variety of reasons: perceived difficulties associated with HBP lead implantation, lead dislodgement, and concern for progression in atrioventricular (AV) conduction system disease. Fibrosis is known to occur near the tip of the actively fixed RV leads. Concern that fibrosis will compromise reliable His bundle capture is one additional factor limiting broad adoption of permanent HBP. Long-term follow-up of permanent HBP has not been reported in the literature. The aim of our study is to assess His bundle capture and its effect on LV function in mediumto long-term follow-up and to determine His-Purkinje conduction at the time of pulse generator change (GC) in patients with chronic
HBP.
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METHODS

Patients
Permanent HBP has been performed at Geisinger Wyoming Valley
Medical Center since 2006. Our analysis involved patients who had undergone successful permanent HBP between the years 2006 and 2014 and presented subsequently for GC due to routine battery depletion. All patients provided written informed consent prior to implantation. This was a retrospective study approved by the institutional review board.
Implantation technique
A detailed description of the permanent HBP has been described previously. 9 Briefly, a 4.1-Fr bipolar active fixation lead (SelectSecure, model 3830, Medtronic Inc., Minneapolis, MN, USA) was implanted in the His bundle region using a dedicated delivery sheath (deflectable C304 or C315His, Medtronic). Selective HBP (S-HBP) was defined as ventricular activation occurring solely over the His-Purkinje system:
(1) His-Purkinje mediated cardiac activation and repolarization as evidenced by electrocardiographic concordance of QRS and T wave complexes; and (2) the paced-ventricular interval was almost identical to the His-ventricular interval (Figure 1 ). Nonselective HBP was (NS-HBP) defined based on capture of basal ventricular septum in addition to His bundle capture as: (1) no isoelectric interval between pacing stimulus and QRS; (2) the electrical axis of the paced QRS must be concordant with the electrical axis of the spontaneous QRS (if known); and (3) narrowing of QRS with higher output or vice versa ( Figure 2 ). [10] [11] [12] The HBP lead was connected to the RV port (no back-up lead) or the left ventricular port in a patient with cardiac resynchronization therapy (CRT) device (RV lead in RV port). Our definition of NS-HBP is different from the initial description of para-Hisian pacing 4, 13 to eliminate the confusion associated with using para-Hisian capture 14 in reference to assessment of accessory pathway conduction.
Protocol
His bundle capture threshold, R wave amplitudes, pacing impedances, and His-ventricular (HV) intervals were measured at implant. Twelvelead electrocardiogram at baseline and during HBP, along with baseline and paced QRS duration, were also recorded for each patient.
In patients with sinus node dysfunction, ventricular pacing avoidance algorithm was routinely used. Patients were followed in device clinic at 2 weeks, 2 months, 1 year, and yearly thereafter. R wave amplitudes, At the time of pulse GC, His bundle capture threshold, R wave amplitudes, pacing impedances, and HV intervals from the HBP lead were again measured. In addition, pacing from HBP lead was routinely performed at cycle lengths of 700 ms, 600 ms, and 500 ms to assess for 1:1
His bundle capture and conduction, 15 during GC ( Figure 3 ). 
Echocardiography
Follow-up
Urgent care visits or hospitalization for heart failure during follow-up were documented. Any new development of AF was recorded.
Statistical analysis
Continuous data are presented as mean ± standard deviation. Differences between continuous variables were assessed using paired Student's t-test. The statistical significance was defined as a P-value <0.05.
RESULTS
Patient characteristics
Between the years 2006 and 2014, a total of 425 patients underwent HBP at our institution. Of these, 20 consecutive patients with previously successful permanent HBP presented for pulse GC due to battery depletion and were included in our analysis. Baseline clinical characteristics along with findings at the time of GC are summarized in Table 1 . The primary indication for permanent pacing was AV nodal 
Pacing characteristics
S-HBP was achieved in seven (35%) patients and NS-HBP in 13 (65%).
Baseline QRS duration was 102 ± 27 ms and the paced (HBP) QRS duration prolonged to 117 ± 20 ms at implant (P = 0.04). At the time of GC, the paced QRS duration and morphology did not differ significantly when compared to at implant (118 ± 23 ms, P = 0.5). His bundle capture threshold at implant was 1.95 ± 1.1 V @ 0.5 ms. At the time of GC, the HBP threshold was higher at 2.5 ± 1.2 V @ 0.5 ms (P = 0.02).
His bundle capture thresholds in patients with S-HBP and NS-HBP
were not significantly different at implant (1.6 ± 0.5 V vs 2.1 ± 1.3 V, P = 0.2) or at GC (2.4 ± 1.0 V vs 2.5 ± 1.3 V, P = 0.7). In one patient 
Echocardiographic data
Baseline and follow-up echocardiograms were available in all patients.
Baseline LVEF was 50 ± 14% and during last follow-up the EF was 55 ± 6% (P = 0.06) ( Figure 5 ). In the six patients with LV dysfunction at baseline, the EF improved from 36 ± 12% to 50 ± 7% during the last followup (P = 0.03). LV end-diastolic diameter improved from 51 ± 8 mm at baseline to 47 ± 7 mm at last follow-up (P = 0.06). Mitral regurgitation was present in 11 patients (mild 10, moderate one) and tricuspid regurgitation (mild seven, moderate one) in eight patients at baseline.
Only one patient with underlying chronic obstructive pulmonary disease and pulmonary hypertension showed evidence of worsening tricuspid regurgitation (patient 1) from mild at baseline to moderate during follow-up in spite of improved LVEF from 35% at implant to 54%.
No patient showed worsening mitral regurgitation.
Clinical outcome
Two patients (2 and 16) had a heart failure hospitalization (HFH) during follow-up. In patient 2, HFH was secondary to worsening renal func- 
DISCUSSION
In this study, we present medium-to long-term follow-up on 20 patients with permanent HBP who presented for GC. This allowed us a unique opportunity to assess the effects of long-term HBP on pacing characteristics and His-Purkinje conduction. During a mean follow-up of 70 ± 24 months, His bundle capture thresholds remained relatively stable with only a modest increase in pacing output (0.6 V). One of the concerns of permanent HBP had been historically high pacing thresholds and early battery depletion. Despite the average pacing thresholds similar to those reported by other investigators, 16 ,17 the device longevity was longer in this series. Most investigators used a back-up RV pacing lead, thus requiring a biventricular or dual-chamber device leading to additional battery depletion. We did not routinely place a back-up RV lead thus limiting current drain. Early in our experience, we programmed a pacing output twice the safety margin. Subsequently we changed our approach to program a pacing output at 1 V above chronic His bundle capture (3-month) threshold at 1-ms pulse duration. In seven of these patients we had used the largest battery available from the manufacturer (Adapta L and EnRhythm TM , Medtronic
Inc.) to combat early battery depletion. Unfortunately, five of these devices had an advisory for premature battery depletion, despite minimal ventricular pacing in four. Midway through this series, we learned to use the C315His sheath for implanting the HBP lead, which generally provides better pacing thresholds than those obtained using the C304 sheath. 9 Currently, we are able to obtain lower His bundle capture thresholds in >50% of the patients by demonstrating acute His bundle injury current at implant. 18 In addition, our current practice is to primarily use the larger battery device. It is well established that chronic RVP is detrimental to left ventricular function and is associated with heart failure and increased mortality. [1] [2] [3] While biventricular pacing is beneficial compared to RV F I G U R E 5 LVEF, LVEDD, QRS duration, and HV intervals at baseline compared to at the time of generator change. There was no statistical difference between the two groups. *The HBP QRS duration was significantly longer at implant and GC when compared to baseline. GC, generator change; HBP, His bundle pacing; HV, His-ventricular; LV, left ventricular; LVEF, LV ejection fraction; LVEDD, LV end-diastolic diameter pacing in patients with heart failure, 21 it has not been proven to prevent HFH or improve mortality in patients without LV dysfunction or heart failure. 22, 23 However, in patients with systolic heart failure and QRS duration <130-150 ms, HFH or mortality do not improve with biventricular pacing and even show worsening of their condition. 24, 25 In these cases, HBP may be effective in ameliorating heart failure.
In our series, there was a nonsignificant increase in LVEF during long-term follow-up despite high HBP burden (77%). This was primarily due to a significant increase in EF in the six patients with underlying LV dysfunction (P = 0.02). The improvement in LVEF could be attributed to HBP in four patients (left bundle branch block in one, pacing-induced cardiomyopathy in one, AF related in two). In the 16 patients with normal LV function, EF remained unchanged (P = 0.96). Previous studies have shown that permanent HBP maintains LV synchrony, left ventricular performance, myocardial perfusion, and prevent heart failure during short-and medium-term follow-up compared to RVP. [4] [5] [6] [7] 11 Several small series have shown improvement in LV function with permanent HBP in patients with traditional indication for CRT. 26, 27 It is possible that HBP may provide an alternative option for patients requiring CRT. In addition, our study shows that there is no significant worsening of valve regurgitation. The HBP lead is primarily located in the right atrium with minimal or no interference to the tricuspid valve. [28] [29] [30] RVP has been associated with new tricuspid regurgitation and valve abnormalities due to fibrous lesions between the lead and the tricuspid valve in addition to pulmonary hypertension resulting from LV dysfunction. 31 A recent study showed reduced incidence of tricuspid valve abnormalities and venous stenosis with the Medtronic 3830 pacing lead compared to traditional RV pacing leads attributed to the smaller lead diameter (4.1 Fr). 32 During the entire follow-up period, there were only two HFHs in our series despite high HBP burden. In a study of 304 patients with normal LV function and AV block, Zhang et al. 33 showed that 26% of patients developed new-onset heart failure during a median follow-up of 7.8 years of RVP. Both of our patients with HFH (patients 2 and 16) had S-HBP and improved LV function at the time of their hospitalization.
It is unlikely that HBP contributed to the HFH in these patients. It is likely that permanent HBP may provide an excellent option for the majority of patients requiring ventricular pacing in the future.
Limitations
This was a small, single-center, retrospective, observational series 
CONCLUSIONS
